Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Fertility preservation for patients with breast cancer: The Korean Society for Fertility Preservation clinical guidelines

  • Kim, Hoon (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kim, Seul Ki (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Lee, Jung Ryeol (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Hwang, Kyung Joo (Department of Obstetrics and Gynecology, Ajou University School of Medicine) ;
  • Suh, Chang Suk (Department of Obstetrics and Gynecology, Seoul National University College of Medicine) ;
  • Kim, Seok Hyun (Department of Obstetrics and Gynecology, Seoul National University College of Medicine)
  • Received : 2017.03.01
  • Accepted : 2017.07.05
  • Published : 2017.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

With advances in the methods of cancer treatment used in modern medicine, the number of breast cancer survivors has been consistently rising. As the number of women who wish to become pregnant after being diagnosed with breast cancer increases, it is necessary to consider fertility preservation in these patients. However, medical doctors may be unaware of the importance of fertility preservation among cancer patients because most patients do not share their concerns about fertility with their doctors. Considering the time spent choosing and undergoing treatment, an early referral to a reproductive specialist is the best way to prevent a delay in cancer treatment. Since it is not easy to make decisions on matters related to cancer diagnosis and fertility, patients should be provided with enough time for decision-making, and to allow for this, an early referral will provide patients with sufficient time to choose an appropriate method of fertility preservation. The currently available options of fertility preservation for patients with breast cancer include cryopreservation of embryos, oocytes, and ovarian tissue and gonadotropin-releasing hormone agonist treatment before and during chemotherapy. An appropriate method of fertility preservation must be selected through consultations between individual patients and health professionals and analyses of the pros and cons of different options.

Keywords

References

  1. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010;28:4683-6. https://doi.org/10.1200/JCO.2010.30.5748
  2. National Cancer Center. Annual report of cancer statistics in Korea in 2014. Sejong: Ministry of Health and Welfare; 2016.
  3. Min SY, Kim Z, Hur MH, Yoon CS, Park EH, Jung KW, et al. The basic facts of Korean breast cancer in 2013: results of a nationwide survey and breast cancer registry database. J Breast Cancer 2016;19:1-7. https://doi.org/10.4048/jbc.2016.19.1.1
  4. American Cancer Society. Breast cancer facts and figures 2015-2016. Atlanta: American Cancer Society; 2015.
  5. Klock SC, Zhang JX, Kazer RR. Fertility preservation for female cancer patients: early clinical experience. Fertil Steril 2010;94:149-55. https://doi.org/10.1016/j.fertnstert.2009.03.028
  6. Thewes B, Meiser B, Taylor A, Phillips KA, Pendlebury S, Capp A, et al. Fertility- and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005;23:5155-65. https://doi.org/10.1200/JCO.2005.07.773
  7. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 2005;23:766-73. https://doi.org/10.1200/JCO.2005.01.134
  8. Partridge AH, Gelber S, Peppercorn J, Sampson E, Knudsen K, Laufer M, et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004;22:4174-83. https://doi.org/10.1200/jco.2004.22.14_suppl.4174
  9. Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA Jr, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med 2016;14:1. https://doi.org/10.1186/s12916-015-0545-7
  10. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-10. https://doi.org/10.1200/JCO.2013.49.2678
  11. Munoz M, Santaballa A, Segui MA, Beato C, de la Cruz S, Espinosa J, et al. SEOM clinical guideline of fertility preservation and reproduction in cancer patients (2016). Clin Transl Oncol 2016;18:1229-36. https://doi.org/10.1007/s12094-016-1587-9
  12. Kim J, Mersereau JE. Early referral makes the decision-making about fertility preservation easier: a pilot survey study of young female cancer survivors. Support Care Cancer 2015;23:1663-7. https://doi.org/10.1007/s00520-014-2526-3
  13. McLaren JF, Bates GW. Fertility preservation in women of reproductive age with cancer. Am J Obstet Gynecol 2012;207:455-62. https://doi.org/10.1016/j.ajog.2012.08.013
  14. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29. https://doi.org/10.1200/JCO.1996.14.5.1718
  15. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N Engl J Med 2000;343:1086-94. https://doi.org/10.1056/NEJM200010123431506
  16. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010;116:791-8. https://doi.org/10.1002/cncr.24835
  17. Berliere M, Duhoux FP, Dalenc F, Baurain JF, Dellevigne L, Galant C, et al. Tamoxifen and ovarian function. PLoS One 2013;8:e66616. https://doi.org/10.1371/journal.pone.0066616
  18. Kim H, Han W, Ku SY, Suh CS, Kim SH, Choi YM. Feature of amenorrhea in postoperative tamoxifen users with breast cancer. J Gynecol Oncol 2017;28:e10. https://doi.org/10.3802/jgo.2017.28.e10
  19. von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, et al. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril 2009;92:1360-5. https://doi.org/10.1016/j.fertnstert.2008.08.011
  20. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013;100:1673-80. https://doi.org/10.1016/j.fertnstert.2013.07.1992
  21. Kim JH, Kim SK, Lee HJ, Lee JR, Jee BC, Suh CS, et al. Efficacy of random-start controlled ovarian stimulation in cancer patients. J Korean Med Sci 2015;30:290-5. https://doi.org/10.3346/jkms.2015.30.3.290
  22. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril 2013;100:1224-31. https://doi.org/10.1016/j.fertnstert.2013.08.041
  23. Borini A, Lagalla C, Bonu MA, Bianchi V, Flamigni C, Coticchio G. Cumulative pregnancy rates resulting from the use of fresh and frozen oocytes: 7 years' experience. Reprod Biomed Online 2006;12:481-6. https://doi.org/10.1016/S1472-6483(10)62002-0
  24. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril 2010;93:391-6. https://doi.org/10.1016/j.fertnstert.2009.02.067
  25. Kim TJ, Laufer LR, Hong SW. Vitrification of oocytes produces high pregnancy rates when carried out in fertile women. Fertil Steril 2010;93:467-74. https://doi.org/10.1016/j.fertnstert.2008.12.094
  26. Checa Vizcaino MA, Corchado AR, Cuadri ME, Comadran MG, Brassesco M, Carreras R. The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. Reprod Biomed Online 2012;24:606-10. https://doi.org/10.1016/j.rbmo.2012.02.020
  27. Domingo J, Guillen V, Ayllon Y, Martinez M, Munoz E, Pellicer A, et al. Ovarian response to controlled ovarian hyperstimulation in cancer patients is diminished even before oncological treatment. Fertil Steril 2012;97:930-4. https://doi.org/10.1016/j.fertnstert.2012.01.093
  28. Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 2016;101:1364-71. https://doi.org/10.1210/jc.2015-3878
  29. Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab 2006;91:3885-90. https://doi.org/10.1210/jc.2006-0962
  30. Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol 2013;29:993-6. https://doi.org/10.3109/09513590.2013.819083
  31. Turan V, Bedoschi G, Moy F, Oktay K. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients. Fertil Steril 2013;100:1681-5.e1. https://doi.org/10.1016/j.fertnstert.2013.08.030
  32. Tatsumi T, Jwa SC, Kuwahara A, Irahara M, Kubota T, Saito H. No increased risk of major congenital anomalies or adverse pregnancy or neonatal outcomes following letrozole use in assisted reproductive technology. Hum Reprod 2017;32:125-32.
  33. Donnez J, Dolmans MM. Ovarian cortex transplantation: 60 reported live births brings the success and worldwide expansion of the technique towards routine clinical practice. J Assist Reprod Genet 2015;32:1167-70. https://doi.org/10.1007/s10815-015-0544-9
  34. Bigorie V, Morice P, Duvillard P, Antoine M, Cortez A, Flejou JF, et al. Ovarian metastases from breast cancer: report of 29 cases. Cancer 2010;116:799-804. https://doi.org/10.1002/cncr.24807
  35. Pimentel C, Becquet M, Lavoue V, Henno S, Leveque J, Ouldamer L. Ovarian metastases from breast cancer: a series of 28 cases. Anticancer Res 2016;36:4195-200.
  36. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-54. https://doi.org/10.1634/theoncologist.12-9-1044
  37. Blumenfeld Z, Zur H, Dann EJ. Gonadotropin-releasing hormone agonist cotreatment during chemotherapy may increase pregnancy rate in survivors. Oncologist 2015;20:1283-9. https://doi.org/10.1634/theoncologist.2015-0223
  38. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA 2015;314:2632-40. https://doi.org/10.1001/jama.2015.17291
  39. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014;40:675-83. https://doi.org/10.1016/j.ctrv.2013.12.001
  40. Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA Jr, Ugolini D, et al. Ovarian suppression using luteinizing hormone- releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a metaanalysis of randomized studies. Ann Oncol 2015;26:2408-19.
  41. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:65-73. https://doi.org/10.1001/jamaoncol.2015.3251
  42. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, et al. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat 2017;165:151-9. https://doi.org/10.1007/s10549-017-4288-3
  43. Quintero RB, Helmer A, Huang JQ, Westphal LM. Ovarian stimulation for fertility preservation in patients with cancer. Fertil Steril 2010;93:865-8. https://doi.org/10.1016/j.fertnstert.2008.10.007
  44. Oktay K. An individualized approach to fertility preservation in women with cancer. J Support Oncol 2006;4:181-4.
  45. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630-5. https://doi.org/10.1200/JCO.2007.14.8700

Cited by

  1. Investigation of Each Society for Fertility Preservation in Asia vol.10, pp.None, 2017, https://doi.org/10.3389/fendo.2019.00151
  2. The psychological importance of fertility preservation counseling and support for cancer patients vol.98, pp.5, 2017, https://doi.org/10.1111/aogs.13562
  3. Oncofertility to Evidence‐Based Practice: Changes in Fertility Intention and Symptom Burden in Reproductive‐Age Women With Breast Cancer vol.16, pp.5, 2017, https://doi.org/10.1111/wvn.12374
  4. Controlled ovarian hyperstimulation for fertility preservation in women with breast cancer: Practical issues vol.48, pp.1, 2021, https://doi.org/10.5653/cerm.2020.03594